News
18h
Barchart on MSNEli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
3h
ThePrint on MSNBig pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin marketThe size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...
Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...
The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...
A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...
Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...
The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results